Stock INMB INMUNE BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages INmune Bio, Inc.

Equities

INMB

US45782T1051

Market Closed - Nasdaq
Other stock markets
 21:30:01 06/05/2024 BST 		5-day change 1st Jan Change
11.2 USD -3.20% Intraday chart for INmune Bio, Inc. -4.84% -0.53%
04-30 INmune Bio, Inc. Provides Update on Two Patients from the Phase 1b Alzheimer's Disease Trial CI
04-29 INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune?? Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
INmune Bio, Inc. Provides Update on Two Patients from the Phase 1b Alzheimer's Disease Trial
INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune?? Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
Inmune Bio Inc. Announces 24-Month Stability Validation of Xpro? for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay
INmune Bio Inc. Presents Data on INB03's Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
INmune Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
INmune Bio, Inc. Reports Significant EEG Improvement in Alzheimer's Patients Treated with XPro
Inmune Bio Announces FDA Removal of Clinical Hold for Alzheimer?S Disease Program
ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology
INmune Bio, Inc. Announces First Patient Dosed in Phase 1/2 Study of INKmune in Patients with Metastatic Castration-Resistant Prostate Cancer
Sector Update: Health Care Stocks Gain Premarket Tuesday
Looming Inflation Data Stifle US Equity Futures Pre-Bell
Sector Update: Health Care
Top Premarket Decliners
INmune Bio Alzheimer's Treatment Remains on Clinical Hold After FDA Requests Information; Shares Slump After Hours
INmune Bio, Inc. Provides Update Regarding Global Alzheimer's Phase Ii Clinical Trial and Clinical Hold Issued by the United States FDA
Inmune Bio Inc. Demonstrates That INB03 Enhances the Uptake of Trastuzumab Deruxtecan in Her2+ Breast Cancer with Muc4 Expression in Poster Presented At San Antonio Breast Cancer Symposium
INmune Bio Gets Authorization in France, Spain for Phase II Trial of XPro for Early Alzheimer's Disease
INmune Bio, Inc. Receives EMA's Authorization in France and Spain for Phase II Clinical Trial of XPro for Early Alzheimer's Disease
INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer's Disease in Europe
INmune Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. INMB Stock
  4. News INmune Bio, Inc.
  5. Other languages